((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-(tetrahydrofuran-3-ylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl nitrate | 1254160-15-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: ((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-(tetrahydrofuran-3-ylamino)-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl nitrate
• 英文别名: [(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(oxolan-3-ylamino)purin-9-yl]oxolan-2-yl]methyl nitrate
• CAS: 1254160-15-0
• 化学式: C₁₄H₁₈N₆O₇
• 分子量: 382.333
• InChiKey: QKLWYFLDTCIMJQ-HVMNINKTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  170
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• [EN] METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION<br/>[FR] PROCÉDÉS DE PRÉVENTION, DE RÉDUCTION OU DE TRAITEMENT DE LA DÉGÉNÉRESCENCE MACULAIRE
  申请人：INOTEK PHARMACEUTICALS CORP

  公开号：WO2016090005A1

  公开（公告）日：2016-06-09

  The present invention is directed to selective adenosine A1 agonist compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, reduce or prevent age-related macular degeneration.

  本发明涉及选择性腺苷A1激动剂化合物，包括这种化合物的药物组合物，以及使用这种化合物来治疗、减少或预防年龄相关性黄斑变性的方法。
• [EN] METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS<br/>[FR] PROCÉDÉ DE RÉDUCTION DE LA PRESSION INTRAOCULAIRE CHEZ LES HUMAINS
  申请人：INOTEK PHARMACEUTICALS CORP

  公开号：WO2010127210A1

  公开（公告）日：2010-11-04

  Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for reducing intraocular pressure comprising administering an effective amount of compounds of Formula I to a subject in need thereof.

  本文提供了公式I的化合物，包含有效量的公式I化合物的组合物，以及用于降低眼压的方法，包括向需要的受试者施用公式I化合物的有效量。
• COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE
  申请人：KIM Norman N.

  公开号：US20110172177A1

  公开（公告）日：2011-07-14

  The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A 1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.

  本发明涉及一种组合物或套装，包括一种前列腺素类似物和一种腺苷受体A1激动剂，以及使用该组合物或套装减少受试者眼内压（IOP）的方法。该发明特别涉及一种拉他诺前列醇（Xalatan™品牌上市）和化合物A的组合。
• Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
  申请人：Jagtap Prakash

  公开号：US20090062314A1

  公开（公告）日：2009-03-05

  The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.

  本发明涉及嘌呤衍生物；包含有效量的嘌呤衍生物的组合物；以及用于减少动物的新陈代谢率、在心肌保护期间保护动物心脏免受心肌抑制损伤的方法；或用于治疗或预防心血管疾病、神经系统疾病、缺血性疾病、再灌注损伤、肥胖症、消耗性疾病或糖尿病的方法，包括向需要的动物施用有效量的嘌呤衍生物。
• METHOD OF REDUCING INTRAOCULAR PRESSURE IN HUMANS
  申请人：BARMAN Shikha

  公开号：US20100279970A1

  公开（公告）日：2010-11-04

  Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for reducing intraocular pressure comprising administering an effective amount of compounds of Formula I to a subject in need thereof.

  本文提供的是I式化合物、包含有效量I式化合物的组合物以及减少眼压的方法，该方法包括向需要的受体中施用有效量的I式化合物。